Research output per year
Research output per year
Research Output
- 1 - 50 out of 70 results
Search results
-
2024
Multi-Cancer Early Detection Testing (MCED)
Gordon, O. K., Bott, B., Parseghian, N., Psychogios, P., Childers, K. K. & Brown, S., Jan 1 2024Research output: Other contribution
File10 Downloads (Pure) -
Population Screening for High-Risk Patient Identification Partnership with CARE-Comprehensive Assessment, Risk, and Education.
Gordon, O. K., Bott, B., Parseghian, N., Childers, K. K. & Brown, S., Jan 1 2024Research output: Other contribution
File10 Downloads (Pure) -
2023
Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) in patients with recurrent platinum refractory/resistant ovarian cancer (041)
Bockorny, B., O'Day, S., Margolin, K., Sanborn, R. E., Kristedja, T. S. & comments, S. A. A. I., Sep 1 2023Research output: Other contribution
-
Diagnostic cell-free miRNA Signatures Found in Plasma and Urine of Sporadic Renal Cell Carcinoma Patients
Bustos, M., Gottlieb, J., Suyeon, R., Allen, W., Krasne, D., Wilson, T., Linehan, J. & Hoon, D., Jan 1 2023Research output: Other contribution
-
Lucchesi O, Ruete MC, Mayorga LS, and Tomes CN
Bustos, M., Jan 1 2023Research output: Other contribution
-
Monitoring 1q21.3 amplification in circulating tumor DNA from metastatic melanoma patients receiving immune checkpoint inhibitor therapies
Hoon, D., Lin, S., Kobayashi, Y., Zhang, X., Yu, Q., O’Day, S. & Bustos, M., Jan 1 2023Research output: Other contribution
-
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes. ASCO, Abst:3128, 6/2023.
Warnecke, B., Hoon, D. & comments, S. F. L. O. A. I., Jun 1 2023Research output: Other contribution
-
Pan-cancer associations of B7-H3 (CD276) transcriptioinal expression across human malignancies. ASCO, Abst:2624, 6/2023.
Hwang, J., Hoon, D. & comments, S. F. L. O. A. I., Jun 1 2023Research output: Other contribution
-
Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
Moon, J., Sanborn, R., Hoon, D. & comments, S. F. L. O. A. I., Nov 1 2023Research output: Other contribution
-
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).
El-Khoueiry, A. B., Margolin, K. A., Sanborn, R. E. & comments, S. A. A. I., Jan 1 2023Research output: Other contribution
-
The 16th International Congress of the Society for Melanoma Research (SMR), November 20-23, 2019
Bustos, M., Jan 1 2023Research output: Other contribution
-
“Impact of Her2 Low on Survival in Patients Treated with Standard Therapies in Advanced Breast Cancer”
Graff, S., Rani, B., Tolulope, A., Andrew, E., Phillip, W., Bustos, M., Estelamari, R. & comments, S. F. L. O. A. I., Jan 1 2023Research output: Other contribution
-
“UBQLN4 triggers MRE11a and STING proteasomal degradation during cisplatin-induced DNA damage response in solid tumors
Hoon, D., Shiloh, Y., Murakami, T., Kobayashi, Y., Jachimowicz, R. & Bustos, M., Jan 1 2023Research output: Other contribution
-
2022
778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors
Wilky, B., Margolin, K., Rachel E, S., O'Day, S. & comments, S. F. L. O. A. I., Jan 1 2022Research output: Other contribution
-
"Cisplatin-induced DNA damage triggers MRE11a proteasomal degradation mediated by UBQLN4 in solid tumors"
Hoon, D., Shiloh, Y., Murakami, T., Kobayashi, Y. & Bustos, M., Jan 1 2022Research output: Other contribution
-
Design and Validation of a Whole-Genome SequencingBased Assay for Population Health
Welle, J., Piening, B., Wagner, J., I, L.-B., Ward, T., B, C., Shull, E., R, R., Pukay, M., Ricks, M., K, C., J, L., M, C., Gordon, O. & Bifulco, C., Nov 1 2022Research output: Other contribution
-
Geno4ME: establishment of an equitable whole-genome sequencing-based platform for clinical screening in a large healthcare system
Wagner, J., I A., L.-B., K R., E., B A., C., Welle, J. T., K, J., N D., W., J, R., Dickey, L., K G., J., L, Y., E M., S., J, C., Vartanian, K., A T., M., M B., C., Piening, B., Bifulco, C. & Gordon, O. K., Oct 25 2022Research output: Other contribution
-
“Cell-Free MicroRNAs as Blood Biomarkers for Aggressive Tumors”
Bustos, M., Jan 1 2022Research output: Other contribution
-
“Genomic and Transcriptomic Mutational Landscapes of HER2-Low Breast Cancer Patients”
Bansal, R., McGrath, J., Bustos, M., Rodriguez, E., Sammons, S., Accordino, M., Meisel, J. & comments, S. F. L. O. A. I., Dec 1 2022Research output: Other contribution
-
“IFI16 promotes immune responses through IFN-γ pathway activation in metastatic cutaneous melanomas”
Kobayashi, Y., Bustos, M., Yu, Q. & Hoon, D., Nov 10 2022Research output: Other contribution
-
“Molecular characterization of UBQLN4 and clinical implications”
Bustos, M., Jan 1 2022Research output: Other contribution
-
2021
398 neoIRX: a phase II trial of locoregional cytokine therapy to promote immunologic priming and clinical response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)
Sanchez, K., Conlin, A., Peddi, P., Stanton, S., Ruzich, J., Kelly S, P., Wu, Y., Moxon, N., Mellinger, S., Sun, Z., Redmond, W. L. & David B, P., Jan 1 2021Research output: Other contribution
-
OT1-18-03. The neoIRX trial:locoregional cytokine therapy to promote immunologic priming and enhanced response to neoadjuvant pembrolizumab plus chemotherapy in triple negative breast cancer (TNBC)
Sanchez, K., Conlin, A., Peddi, P., Stanton, S., Ruzich, J., Kelly S, P., Wu, Y., Moxon, N., Mellinger, S., Sun, Z., Redmond, W. L. & David B, P., Dec 1 2021Research output: Other contribution
-
2020
MP70-07 TRANSPERINEAL FOCAL CRYOABLATION AS A TREATMENT FOR CLINICALLY SIGNIFICANT PROSTATE CANCER
Kelly, M. J. & Torrez, J., May 19 2020Research output: Other contribution
-
2018
A Tale of Two Bladders- High-Grade Non-muscle Invasive Bladder Cancer and Muscle Invasive Bladder Cancer: Evolving treatment paradigms
Kelly, M. J., Apr 11 2018Research output: Other contribution
-
Current Management Options for Pathological Stage IA and IB Seminoma
Kelly, M., 2018Research output: Other contribution
-
Focal Ablation for Locally Advance Prostate Cancer
Kelly, M. J., Mar 5 2018Research output: Other contribution
-
Newly Diagnosed Prostate Cancer…What you need to know
Kelly, M., 2018Research output: Other contribution
-
“YBX1 binding to ILF2 modulates DNA-Damaging ChemoTherapeutics Response in Metastatic Breast Cancer
Bustos, M., Zhang, X. & Hoon, D., Oct 1 2018Research output: Other contribution
-
2017
Clinical Stage I vs Clinical Stage II Seminoma. Nuances and Assessing Treatment Guidelines
Kelly, M. J., Apr 13 2017Research output: Other contribution
-
Extended Endonasal Transsellar Transplanum Endoscopic Removal of Craniopharyngioma. VideoEndocrinology (2017).
Kelly, D. & Griffiths, C. F., 2017Research output: Other contribution
-
2015
Endonasal Endoscopic Surgery for Pituitary Adenoma. VideoEndocrinology (2015).
Griffiths, C. F. & Kelly, D., 2015Research output: Other contribution
-
Nephron Sparing Surgery vs Ablation for Hilar Renal Cell Carcinoma. Case Presentation and Literature Review
Kelly, M. J., Jan 1 2015Research output: Other contribution
-
The Evaluation and Management of Urinary Retention in the Acute Care Setting
Kelly, M. J., Nov 11 2015Research output: Other contribution
-
Tumor Board Presentation; Topics: 1. Current Management of Renal Angiomyolipoma 2. Update of NCCN Management of Pathological T2 Bladder Cancer
Kelly, M. J., Nov 12 2015Research output: Other contribution
-
2014
Active Surveillance for Men with Low-Risk Adenocarcinoma of the Prostate. “Who Is a Candidate for Surveillance, Who Is Not?”
Kelly, M. J., Sep 11 2014Research output: Other contribution
-
Reconciling the R.E.N.A.L. Nephrometry Tool and the updated NCCN Management Guidelines for Kidney Cancer. “Upholding Oncological Principles and Avoiding Chronic Kidney Disease.”
Kelly, M. J., Dec 11 2014Research output: Other contribution
-
Squamous Cell Carcinoma of the Penis. Natural History, Epidemiology, Diagnosis, Staging and Management
Kelly, M. J., Apr 10 2014Research output: Other contribution
-
The use of multiparimetric MRI Imaging in the Management of Clinically Localized Prostate Cancer
Kelly, M. J., Sep 8 2014Research output: Other contribution
-
2013
IMMUNOLOGICAL MARKERS FOR ADJUVANT THERAPY IN MELANOMA
Hoon, D. S. B., Morton, D. L., Chiu, C. G. & Chong, K., May 16 2013Research output: Other contribution
-
MOLECULAR MALIGNANCY IN MELANOCYTIC LESIONS
Wang, H., Roberts, C., Maddula, K., Lu, Z., Brown, J., Vasicek, T., Kerns, B. J., Seligmann, B. & Hoon, D. S. B., Jun 24 2013Research output: Other contribution
-
2012
LONG NONCODING RNA (LNCRNA) AS A BIOMARKER AND THERAPEUTIC MARKER IN CANCER
Hoon, D. S. B. & Lessard, L., Nov 30 2012Research output: Other contribution
-
“A Rab-GEF cascade during human sperm exocytosis
Bustos, M., Lucchesi, O., Ruete, M., Mayorga, L., and, T. & CN, A., Oct 1 2012Research output: Other contribution
-
2011
Direct blood assay for detection of circulating microrna in cancer patients
Hoon, D. S. B. & Asaga, S., Sep 22 2011Research output: Other contribution
-
-
2010
B7-h3 antibody coupled bead assay for detection of circulating tumor cells
Hoon, D. S. B., Feb 20 2010Research output: Other contribution
-
B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients
Hoon, D. S. B., Feb 20 2010Research output: Other contribution
-
B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER
Hoon, D. S. B., Aug 26 2010Research output: Other contribution
-
USE OF METHYLATION STATUS OF MINT LOCI AS A MARKER FOR RECTAL CANCER
Hoon, D. S. B. & de Maat, M. F. G., Jan 7 2010Research output: Other contribution
-
2009
Method for predicting response of cancer patient to chemotherapy
Giuliano, A. E., Hoon, D. S., Ishihara, H., アルマンドイー．ジュリアーノ, デイヴエス．フーン & 石原英幹, Aug 24 2009Research output: Other contribution